<rp id="nt1u6"><optgroup id="nt1u6"></optgroup></rp>

      <ruby id="nt1u6"><nav id="nt1u6"></nav></ruby>

      <rt id="nt1u6"><meter id="nt1u6"></meter></rt>

      1. <tt id="nt1u6"><noscript id="nt1u6"></noscript></tt>

        <rt id="nt1u6"><optgroup id="nt1u6"></optgroup></rt>
        <source id="nt1u6"></source>
        <b id="nt1u6"><noscript id="nt1u6"></noscript></b><source id="nt1u6"></source>

        INVENTING A NEW
        ROADMAP FOR BIOTECH

        Every day, we use our homegrown technologies to discover, develop, research and deliver new medicines that help people with serious diseases. Watch to see what drives us.

        Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.

        Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite? technologies, such as VelocImmune? which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

        FOR 30 YEARS, OUR
        MISSION HAS BEEN TO
        USE THE POWER OF
        SCIENCE TO BRING
        NEW MEDICINES TO
        PATIENTS... OVER
        AND OVER AGAIN.

        Neil Stahl, PhD, Executive VP,
        Research and Development

        2018 annual report PDF download

        Check out our 2018 annual materials. The Responsibility Report and Annual Report are now online.

        Read our annual report
        and responsibility report

        2018 responsibility report PDF download

        REGENERON BY THE NUMBERS

        • 30
          years of scientific
          leadership
        • 7,500+
          employees
          worldwide
        • 700+
          employees with
          an MD, PhD or
          PharmD degree
        • 6TH
          consecutive year
          in Forbes' World's
          Most Innovative
          Companies
        • #1
          ranking in Science
          magazine’s global Top
          Employer survey for six
          of the past eight years
        • 31,000+
          employee volunteer hours
          for 100+ organizations
          in 2018
        • 7
          FDA-approved
          medicines
        • 98%
          of our waste
          diverted from
          landfill, surpassing
          our goal
        • 100%
          of drug candidates
          invented and
          developed in-house
        • 700,000+
          exomes sequenced
          to date
        • 100+
          publications in 2018
        • 20+
          product candidates in
          clinical development
          across multiple
          therapeutic areas
        • Shingo Institute: The Shingo Prize, 2019

          Great Places to Work: Best Workplace in Ireland, 2019

          Science: #1 Top Employer, 2018

          Forbes: Top 10 Most Innovative Companies, 2018

          Civic 50: Most Community-Minded Companies in the Nation, 2018

          Fortune: Best Companies to Work for, 2018

        • MIT Technology Review: Top 10 Smartest Companies, 2017

          Fortune: Future 50, 2017

          Barron’s: World’s Best CEOs, 2016

          Scrip Award: R&D Team of the Year, 2016

          Crain’s New York Business: Fast 50, 2015

        LEADERSHIP

        We are the only biopharmaceutical company to be led by physician-scientists for more than 30 years. We consistently demonstrate our commitment to scientific excellence by counting multiple Nobel Laureates and five members of the National Academy of Sciences among our leadership, as well as being one of the first companies to form a Science and Technology Committee as an integral component of its Board, a practice which has since become industry standard.

        Our leadership

        A FOCUS
        ON SCIENCE

        From our first days, science has remained our central guiding principle.

        Our journey

        国产区露脸视频